Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immunovant, Inc. - Common Stock (NQ: IMVT )

22.88 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Immunovant, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
If You Invested $1000 In Vivek Ramaswamy-Founded Roivant When He Declared Presidential Bid, Here's How Much You'd Have Now
Roivant stock has outperformed the broader market and the biotech sector this year, mirroring the rise in the fortunes of its founder Vivek Ramaswamy. 
Via Benzinga
What 11 Analyst Ratings Have To Say About Immunovant
Via Benzinga
Immunovant's FcRn Strategy Gains Momentum: Analysts View ADHERE Study as De-Risking Factor for CIDP Clinical Development
Monday, Argenx SE (NASDAQ: ARGX) reported topline results from the ADHERE study evaluating Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with chronic inflammatory demyelinating... 
Via Benzinga
9 Analysts Have This to Say About Immunovant
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start off the trading week with a breakdown of all the biggest pre-market stock movers worth watching on Monday! 
Via InvestorPlace
HC Wainwright & Co. Maintains Buy Rating for Immunovant: Here's What You Need To Know
Via Benzinga
Immunovant Inc. (NASDAQ: IMVT) is a Stock Spotlight on 5/23
Via Investor Brand Network
Analyst Expectations for Immunovant's Future
Via Benzinga
Activision Blizzard, Argenx And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures traded mixed this morning on Monday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Recap: Immunovant Q4 Earnings
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 1, 2023
Via Benzinga
Analyst Expectations for Immunovant's Future
Via Benzinga
7 Analysts Have This to Say About Immunovant
Via Benzinga
Immunovant Inc. (NASDAQ: IMVT) is a Stock Spotlight on 3/24
Via Investor Brand Network
Analyst Boosts Immunovant Price Target After Updated Pipeline Realignment
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2023
Via Benzinga
Immunovant Could Potentially Be An M&A Target, Writes Analyst
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 15, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 13, 2023
Via Benzinga
Analyst Expectations for Immunovant's Future
Via Benzinga
Universal Health Services, Madrigal Pharmaceuticals And These Overbought Majors In The Healthcare Sector
The most overbought stocks in the healthcare sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
What 6 Analyst Ratings Have To Say About Immunovant
Within the last quarter, Immunovant (NASDAQ:IMVT) has observed the following analyst ratings: 
Via Benzinga
6 Analysts Have This to Say About Immunovant
Over the past 3 months, 6 analysts have published their opinion on Immunovant (NASDAQ:IMVT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
Where Immunovant Stands With Analysts
Immunovant (NASDAQ:IMVT) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Immunovant to Present at Guggenheim 4th Annual Immunology and Neurology Day on November 14th
From Immunovant Inc.
Via GlobeNewswire
Immunovant: Q2 Earnings Insights
Immunovant (NASDAQ:IMVT) reported its Q2 earnings results on Friday, November 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Why Immunovant Stock Is Skyrocketing This Week
The drugmaker announced a $75 million public offering. 
Via The Motley Fool
Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended September 30, 2022
From Immunovant Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.